Plasma lipocalin‐2 levels in the preclinical stage of Alzheimer's disease. Issue 1 (1st December 2019)

• Record Type: Journal Article
• Authors: Eruysal, Emily; Ravdin, Lisa; Kamel, Hooman; Iadecola, Costantino; Ishii, Makoto
• Is Part Of: Alzheimer's & dementia. Volume 11:Issue 1(2019)
• Page Start: 646
• Page End: 653
• Publication Date: 2019-12-01
• Subjects: Alzheimer's disease -- Amyloid beta‐Peptides -- Biomarkers -- Blood -- Dementia -- Immunoassay -- Lipocalin -- NGAL -- Preclinical; Alzheimer's disease -- Periodicals; Alzheimer's disease -- Diagnosis -- Periodicals; Dementia -- Periodicals; Dementia -- Diagnosis -- Periodicals; 616.831
• DOI: 10.1016/j.dadm.2019.07.004
• Languages: English
• ISSNs: 2352-8729

Abstract

Abstract: Introduction: Lipocalin‐2 is an acute‐phase protein with pleotropic functions that has been implicated in several diseases including Alzheimer's disease (AD). However, it is unknown if circulating lipocalin‐2 levels are altered in the preclinical stage of AD, where AD pathology has accumulated but cognition remains relatively intact. Methods: In this cross‐sectional study, we used an immunoassay to measure plasma lipocalin‐2 levels in cognitively normal (Clinical Dementia Rating 0) elderly individuals. 38 of 156 subjects were classified as preclinical AD by cerebrospinal fluid criteria. Results: Plasma lipocalin‐2 levels were higher in preclinical AD compared with control subjects and associated with cerebrospinal fluid amyloid‐beta42 levels but not cerebrospinal fluid tau or phosphorylated‐tau181 levels. Exploratory analyses revealed that plasma lipocalin‐2 was associated with executive function but not episodic memory. Discussion: Collectively, these results raise the possibility that circulating lipocalin‐2 is involved early in AD pathogenesis and may represent an early blood biomarker of amyloid‐beta pathology.